AsianScientist (Jan. 30, 2012) – Takeda Bio Development Center Limited, a subsidiary of Takeda Pharmaceutical Company Limited, has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for the anti-prostate cancer investigational agent, orteronel (TAK-700).
Orteronel, discovered by Takeda, is an oral, non-steroidal androgen synthesis inhibitor that has been shown in pre-clinical studies to selectively inhibit the 17, 20 lyase enzymes which are central to the production of steroidal androgens in the testes and adrenal glands.
Synthesis of androgens outside the testes contributes to disease progression in castration-resistant prostate cancer (CRPC).
The two trials are known as the ELM-PC (Evaluation of the Lyase inhibitor in Metastatic Prostate Cancer) trials.
The first (C21004) is a randomized, double-blind and multi-center trial of prednisolone plus orteronel or placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. The primary endpoints are Overall Survival and Progression Free Survival.
The second (C21005) is a randomized, double-blind and multi-center trial of prednisolone plus TAK-700 or placebo in patients with mCRPC that have progressed during or following docetaxel-based therapy. The primary endpoint is OS.
“We expect orteronel has a potential to become a treatment option for prostate cancer with novel mechanism of action. We will strive to develop this drug as a new treatment to meet unmet medical needs,” said Hiroyasu Nakamura, President of Takeda Bio.
——
Source: Takeda Pharmaceutical Co. Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
